Compare CIX & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIX | ACRS |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.5M | 311.0M |
| IPO Year | 1997 | 2015 |
| Metric | CIX | ACRS |
|---|---|---|
| Price | $24.30 | $3.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 1.9K | ★ 2.3M |
| Earning Date | 06-04-2026 | 05-27-2026 |
| Dividend Yield | ★ 9.05% | N/A |
| EPS Growth | 17.04 | ★ 69.01 |
| EPS | ★ 1.58 | N/A |
| Revenue | ★ $158,285,000.00 | $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.38 | ★ N/A |
| Revenue Growth | ★ 8.46 | N/A |
| 52 Week Low | $17.89 | $1.05 |
| 52 Week High | $32.30 | $4.89 |
| Indicator | CIX | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 51.26 | 55.72 |
| Support Level | $22.97 | $2.76 |
| Resistance Level | $24.90 | $3.78 |
| Average True Range (ATR) | 0.37 | 0.23 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 43.13 | 76.26 |
Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's reportable operating segment includes Security Products and Marine Components. It generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Geographically, the company generates maximum revenue from the United States, followed by Canada, Mexico, and other markets.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.